{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.164","value":"-1.26"},{"groupId":"OG001","spread":"4.623","value":"-0.81"}]}],"title":"Cycle 4 (n=166, 147)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.989","value":"-1.28"},{"groupId":"OG001","spread":"4.378","value":"-0.01"}]}],"title":"Cycle 10 (n=70, 45)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.095","value":"-0.97"},{"groupId":"OG001","spread":"3.768","value":"0.75"}]}],"title":"Cycle 16 (n=47, 24)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.561","value":"-2.44"},{"groupId":"OG001","spread":"5.618","value":"-2.86"}]}],"title":"End of Treatment (n=169, 199)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"199"}],"units":"Participants"}],"description":"The FHSI-8 is a self-administered 8-item questionnaire that measures a participant's symptoms in the domains of jaundice, stomach pain/discomfort weight loss, and fatigue. Participants rated each item on a 5-point scale from 0 (not at all) to 4 (very much). Item scores were calculated as outlined in the FACIT manual. FHSI-8 total score was the sum of each item's score with a total score ranging from 0 (highly symptomatic) to 32 (asymptomatic).","dispersionType":"Standard Deviation","groups":[{"description":"Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG000","title":"Ramucirumab (IMC-1121B) + BSC"},{"description":"Placebo: 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.","id":"OG001","title":"Placebo + BSC"}],"paramType":"MEAN","populationDescription":"Randomized participants who had FHSI-8 at baseline and the specified time points.","reportingStatus":"POSTED","timeFrame":"Baseline, Prior to infusion on Day 1 of Cycle 4, Cycle 10, and Cycle 16 (14-day cycles), and end of treatment (up to 34 months)","title":"Change From Baseline in the Functional Assessment of Cancer Therapy (FACT) Hepatobiliary Symptom Index-8 (FHSI-8)","type":"SECONDARY","unitOfMeasure":"units on a scale"}